September 9, 2020
Virology Placeholder post
(Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)
Read More
August 27, 2020
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
(Oral presentation, EASL International Liver Congress, 27-29 August 2020, Abstract #AS074)
Read More
August 27, 2020
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
(Poster, EASL International Liver Congress, 27-29 August 2020, Abstract #SAT038)
Read More
December 18, 2019
First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities
(Paper, Hepatology 2020)
Read More
September 6, 2019
Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent
(Poster, Obesity Week, 11-15 November 2018, Abstract # T-P-3383)
Read More
September 5, 2019
The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model
(Poster, AASLD The Liver Meeting, 9-13 November 2018, Abstract #734)
Read More
September 3, 2019
Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab
(Poster, ASCO Annual Meeting, 31 May – 4 June 2019, Abstract #2064)
Read More
February 13, 2018
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
(Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)
Read More
October 23, 2017
Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis.
(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994)
Read More
October 23, 2017
Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.
(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972)
Read More